{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:36:03Z","timestamp":1755218163868,"version":"3.43.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>We report the case of a 78-year-old male who was diagnosed with <jats:italic>HOX11<\/jats:italic>-positive acute monocytic leukemia (AML-M5), complicated by leukemic hepatic infiltration and cholestatic liver injury. Initial management included hydroxyurea and liver-protective therapies; however, liver dysfunction progressed despite treatment. With the patient\u2019s liver function deteriorating, chemotherapy with venetoclax and azacitidine was initiated under close monitoring, along with intensive supportive care including methylprednisolone. This regimen choice was based on a careful assessment of the hepatotoxicity profiles of these drugs in conjunction with the patient\u2019s hepatic function. As the leukemic burden decreased, liver function gradually improved, and the patient achieved hematologic recovery sufficient for discharge. This case highlights the challenges of treating elderly AML-M5 patients with hepatic infiltration and emphasizes the importance of early recognition and individualized treatment strategies and the potential benefits of dose-adjusted induction therapy tailored according to the hepatotoxicity profiles of the drugs and the patient\u2019s hepatic function.<\/jats:p>","DOI":"10.3389\/fonc.2025.1620271","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:34Z","timestamp":1754453554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cholestatic liver injury due to leukemic infiltration in HOX11-positive acute monocytic leukemia: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Huiping","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunqing","family":"She","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1988.tb07629.x","article-title":"Diagnostic and prognostic factors in acute monocytic leukaemia: an analysis of 51 cases","volume":"69","author":"Scott","year":"1988","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15542-6","article-title":"Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia","volume":"363","author":"Ferrando","year":"2004","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402892","article-title":"Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children\u2019s Cancer Group (CCG)","volume":"17","author":"Kees","year":"2003","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000120756","article-title":"Liver involvement with acute myeloid leukemia","volume":"2","author":"Mathews","year":"2008","journal-title":"Case Rep Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2019.1877","article-title":"Acute lymphoblastic leukemia in an adolescent presenting with acute hepatic failure: A case report","volume":"11","author":"Gu","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20544","article-title":"Acute lymphoblastic leukemia presenting in fulminant hepatic failure","volume":"47","author":"Litten","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2324709616665866","DOI":"10.1177\/232470961666","article-title":"Acute lymphoblastic leukemia in a young adult presenting as hepatitis and acute kidney injury","volume":"4","author":"Heincelman","year":"2016","journal-title":"J Invest Med High Impact Case Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12221","article-title":"Liver transplantation in an adolescent with acute liver failure from acute lymphoblastic leukemia","volume":"18","author":"Reddi","year":"2014","journal-title":"Pediatr Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2001.021004287.x","article-title":"Acute liver failure as the initial manifestation of acute leukaemia","volume":"21","author":"Anderson","year":"2001","journal-title":"Liver"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22549","article-title":"Abnormal liver transaminases and conjugated hyperbilirubinemia at presentation of acute lymphoblastic leukemia","volume":"55","author":"Segal","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13256-022-03476-7","article-title":"Acute hepatitis-like presentation with cholestasis of CBFB\u2013MYH11-positive acute myeloid leukemia in an adult male: a case report","volume":"16","author":"Spinelli","year":"2022","journal-title":"J Med Case Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.960","article-title":"Acute myeloid leukaemia presenting as acute liver failure-a case report and literature review","volume":"13","author":"Sun","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.013565","article-title":"Acute myeloid leukaemia presenting as cholestatic hepatitis","volume":"57","author":"Wandroo","year":"2004","journal-title":"J Clin Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5009\/gnl.2007.1.2.182","article-title":"Acute myeloid leukemia presenting as obstructive jaundice caused by granulocytic sarcoma","volume":"1","author":"Lee","year":"2007","journal-title":"Gut Liver"},{"key":"B15","article-title":"Acute myeloid leukemia presenting as obstructive jaundice","volume":"49","author":"Rajeswari","year":"2012","journal-title":"Indian Pediatr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2021.100251","article-title":"Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice","volume":"15","author":"Walsh","year":"2021","journal-title":"Leuk Res Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e77223","DOI":"10.7759\/cureus.77223","article-title":"Acute myelomonocytic leukemia: A rare cause of painless jaundice","volume":"17","author":"Joshi","year":"2025","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.979","article-title":"Acute myeloid leukemia presenting with hepatic dysfunction: Should induction be dose reduced","volume":"5","author":"Maharaj","year":"2024","journal-title":"EJHaem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208937","article-title":"Acute liver failure","volume":"369","author":"Bernal","year":"2013","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.31487\/j.CDM.2020.02.01","article-title":"MDCT evaluation of hepatic manifestations in Malignant hematological disorders","volume":"2","author":"El-Badrawy","year":"2020","journal-title":"Clin Diagn Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40265-016-0585-0","article-title":"Azacitidine: A review in myelodysplastic syndromes and acute myeloid leukaemia","volume":"76","author":"Scott","year":"2016","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00746-4","article-title":"Pharmacokinetics of the BCL-2 inhibitor venetoclax in subjects with hepatic impairment","volume":"58","author":"Salem","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3494-3","article-title":"Autopsy findings in patients with acute myeloid leukemia and non-Hodgkin lymphoma in the modern era: a focus on lung pathology and acute respiratory failure","volume":"98","author":"Van de Louw","year":"2019","journal-title":"Ann Hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4251\/wjgo.v14.i3.587","article-title":"Gut and liver involvement in pediatric hematolymphoid Malignancies","volume":"14","author":"Devarapalli","year":"2022","journal-title":"World J Gastrointest Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2010.11.005","article-title":"Leukemia cells invading the liver express liver chemokine receptors and possess characteristics of leukemia stem cells in mice with MPD-like myeloid leukemia","volume":"39","author":"Bigildeev","year":"2011","journal-title":"Exp Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0318","article-title":"The hepatic microenvironment uniquely protects leukemia cells through induction of growth and survival pathways mediated by LIPG","volume":"11","author":"Ye","year":"2021","journal-title":"Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3892\/ijmm.2024.5383","article-title":"Role of lactate and lactate metabolism in liver diseases (Review)","volume":"54","author":"Yao","year":"2024","journal-title":"Int J Mol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2024.00156","article-title":"The multifaceted role of bilirubin in liver disease: A literature review","volume":"12","author":"Ram\u00edrez-Mej\u00eda","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"B31","first-page":"1","article-title":"The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors","volume":"9","author":"Hawley","year":"1994","journal-title":"Oncogene"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509049759","article-title":"Dysregulation of HOX11 by chromosome translocations in T-cell acute lymphoblastic leukemia: a paradigm for homeobox gene involvement in human cancer","volume":"16","author":"Lichty","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.162","article-title":"Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia","volume":"29","author":"Durinck","year":"2015","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20725","article-title":"Hematopoietic immortalizing function of the NKL-subclass homeobox gene TLX1","volume":"49","author":"Zweier-Renn","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1620271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:35Z","timestamp":1754453555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1620271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":36,"alternative-id":["10.3389\/fonc.2025.1620271"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1620271","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1620271"}}